307 related articles for article (PubMed ID: 31791413)
21. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
22. CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice.
Wu X; Guo J; Ding R; Lv B; Bi L
Acta Histochem; 2015 Oct; 117(8):732-7. PubMed ID: 26456520
[TBL] [Abstract][Full Text] [Related]
23. A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF.
Ji J; Xu J; Li F; Li X; Gong W; Song Y; Dou H; Hou Y
Acta Biochim Biophys Sin (Shanghai); 2016 May; 48(5):411-9. PubMed ID: 27121231
[TBL] [Abstract][Full Text] [Related]
24. Sophocarpine attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation.
Li X; Wang M; Hong H; Luo C; Liu Z; Yang R
Immunol Res; 2018 Aug; 66(4):521-527. PubMed ID: 30047025
[TBL] [Abstract][Full Text] [Related]
25. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells.
Qing X; Zavadil J; Crosby MB; Hogarth MP; Hahn BH; Mohan C; Gilkeson GS; Bottinger EP; Putterman C
Arthritis Rheum; 2006 Jul; 54(7):2198-210. PubMed ID: 16804897
[TBL] [Abstract][Full Text] [Related]
26. Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist.
Itto R; Oe Y; Imaruoka K; Sato E; Sekimoto A; Yamakage S; Kumakura S; Sato H; Ito S; Takahashi N
Tohoku J Exp Med; 2019 Oct; 249(2):127-133. PubMed ID: 31666446
[TBL] [Abstract][Full Text] [Related]
27. IL-3 contributes to development of lupus nephritis in MRL/lpr mice.
Renner K; Hermann FJ; Schmidbauer K; Talke Y; Rodriguez Gomez M; Schiechl G; Schlossmann J; Brühl H; Anders HJ; Mack M
Kidney Int; 2015 Nov; 88(5):1088-98. PubMed ID: 26131743
[TBL] [Abstract][Full Text] [Related]
28. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis.
Takahashi S; Nose M; Sasaki J; Yamamoto T; Kyogoku M
J Immunol; 1991 Jul; 147(2):515-9. PubMed ID: 2071894
[TBL] [Abstract][Full Text] [Related]
29. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
30. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
[TBL] [Abstract][Full Text] [Related]
31. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
Anders HJ; Vielhauer V; Eis V; Linde Y; Kretzler M; Perez de Lema G; Strutz F; Bauer S; Rutz M; Wagner H; Gröne HJ; Schlöndorff D
FASEB J; 2004 Mar; 18(3):534-6. PubMed ID: 14734643
[TBL] [Abstract][Full Text] [Related]
32. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
34. Essential Roles for Mannose-Binding Lectin-Associated Serine Protease-1/3 in the Development of Lupus-Like Glomerulonephritis in MRL/
Machida T; Sakamoto N; Ishida Y; Takahashi M; Fujita T; Sekine H
Front Immunol; 2018; 9():1191. PubMed ID: 29892304
[TBL] [Abstract][Full Text] [Related]
35. Fn14 Deficiency Ameliorates Anti-dsDNA IgG-Induced Glomerular Damage in SCID Mice.
Wu J; Min X; Wang L; Yang J; Wang P; Liu X; Xia Y
J Immunol Res; 2018; 2018():1256379. PubMed ID: 30648117
[TBL] [Abstract][Full Text] [Related]
36. Pim-1 as a Therapeutic Target in Lupus Nephritis.
Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
[TBL] [Abstract][Full Text] [Related]
37. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
Kadiombo AT; Maeshima A; Kayakabe K; Ikeuchi H; Sakairi T; Kaneko Y; Hiromura K; Nojima Y
Am J Physiol Renal Physiol; 2017 Feb; 312(2):F297-F304. PubMed ID: 27881396
[TBL] [Abstract][Full Text] [Related]
38. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
[TBL] [Abstract][Full Text] [Related]
39. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
40. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
Chalmers SA; Wen J; Shum J; Doerner J; Herlitz L; Putterman C
Clin Immunol; 2017 Dec; 185():100-108. PubMed ID: 27570219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
